APLI — Appili Therapeutics Share News
0.000.00%
Last trade - 00:00- CA$1.99m
- CA$14.23m
- CA$0.10m
Brief: Appili Therapeutics Announces U.S. FDA Approval Of Likmez Metronidazole Oral Suspension
Brief: Appili Therapeutics Announces Issuance Of Patent For Ati-1501 Liquid Oral Reformulation Of Metronidazole
Brief: Appili Therapeutics Secures Contract For ATI-1701 Funding From The U.S. Air Force Academy
Brief: Appili Therapeutics Reports Financial And Operational Results For Third Quarter Of Fiscal Year 2023
Brief: Appili Therapeutics Announces That FDA Accepts The ATI-1501 NDA
Brief: Appili Therapeutics Gets Notice Of Allowance From The U.S. Patent And Trademark Office For Co's Liquid Oral Reformulation
Brief: Appili Therapeutics Ati-1701 Biodefense Vaccine Secures ~$14 Million Of Funding From U.S. Department Of Defense In Partnership With U.S. Air Force Academy
Brief: Appili Therapeutics Inc As Of September 30, 2022, Company Had Cash Of $2.4 Million, Compared To $6.7 Million On March 31, 2022
Brief: Appili Therapeutics Reports Financial And Operational Results For First Quarter Of Fiscal Year 2023
Brief: Appili Therapeutics Announces Pricing Of Overnight Marketed Equity Offering
Brief: Appili Therapeutics Announces Overnight Marketed Equity Offering
Brief: Appili Therapeutics Reports New Late-Stage Clinical Program ATI-1801 To Treat Cutaneous Leishmaniasis
Brief: Appili Announces Non-Convertible Secured Loan Of US$3.6 Million
Brief: Appili Therapeutics Announces Over Us$10 Million In New Funding From US Department Of Defense For Biodefense Vaccine Candidate ATI-1701
Brief: Appili Therapeutics Expands Ati-1501 Commercial Agreement With Partner Saptalis Pharmaceuticals
Brief: Appili Therapeutics Announces Update To Funding Agreement With The Lind Partners
Brief: Appili Therapeutics Announces Change To Board Of Directors
Brief: Appili Therapeutics Reports Financial And Operational Results For Second Quarter Of Fiscal Year 2022 And Change Of Chief Financial Officer
Aditxt sinks as acquisition target's COVID-19 therapy fails study